National Brain Tumor Society Commends Congressional Awareness Month Resolution National Brain Tumor Society (NBTS) commends the introduction of a resolution in the United States House of Representatives designating May as “National Brain Tumor Awareness Month.” The resolution — (H.Res.980) Expressing support for designation of May 2020 as “National Brain Tumor Awareness Month” — introduced by U.S. Representative Mike Quigley (D-IL-05), is a positive step […] May 29, 2020
National Brain Tumor Society Provides Funding to Expand the Potential of a Promising Therapeutic in Development for Glioblastoma $100,000 grant will support researchers at Cleveland Clinic and Curtana Pharmaceuticals investigating the possible dual action of a novel small molecule drug National Brain Tumor Society (NBTS), a leader in brain tumor patient advocacy, research, information, and support, today announced that it’s providing $100,000 to support research on the novel drug candidate, CT-179, which is […] May 20, 2020
Brain Cancer Groups to Fund Pilot Trial of Individualized Approach to Immunotherapy National Brain Tumor Society and StacheStrong team up to fund clinical testing of a personalized therapeutic vaccine for pediatric and adult high-grade glioma patients National Brain Tumor Society (NBTS), a leader in brain tumor patient advocacy, research, information and support, and StacheStrong, a nonprofit dedicated to raising funds and awareness for brain cancer research, have […] May 12, 2020
Important Update: NBTS Events and COVID-19 (Coronavirus) Last Update: March 9, 2020 National Brain Tumor Society (NBTS) understands that many of our supporters may have questions and concerns related to ongoing news reports about the spread of the novel coronavirus, known as COVID-19. At this time, the U.S. Centers for Disease Control and Prevention (CDC) risk assessment states that: “For most people, […] March 10, 2020
Update on Patient Prescription Assistance for Temodar (Temozolomide) A chemotherapy drug known as Temodar (generic name: temozolomide) is part of the standard of care treatment for many patients with malignant brain tumors. Temodar/temozolomide is one of just a small handful of FDA-approved treatments for brain tumor patients and is the backbone medication for a significant proportion of individuals diagnosed with gliomas, including glioblastoma, […] February 4, 2020